• 1.jpg
  • 2.jpg
  • 4.jpg
  • 5.jpg
  • 6.jpg
  • 7.jpg
  • DSCF6103.jpg
  • DSCF6330.jpg
  • DSCF6361.jpg
  • DSCF6682.jpg
  • DSCF7352.jpg
  • DSCF7463.jpg
  • DSCF7655.jpg
  • DSCF7700.jpg
  • DSCF7758.jpg
  • DSCF7761.jpg
  • 8.jpg
  • 9.jpg

CLINAM 9 / 2016 Conference and Exhibition

European & Global Summit for Cutting-Edge Medicine

June 26 – 29, 2016

Clinical Nanomedicine and Targeted Medicine

Enabling Technologies for Personalized Medicine

Call for Papers and Posters, Call for Exhibitors & University Village

Conference Venue: Congress Center, Messeplatz 21, 4058 Basel, Switzerland
Phone + 41 58 206 28 28  This email address is being protected from spambots. You need JavaScript enabled to view it.
Organizers Office: CLINAM‐Foundation, Alemannengasse 12, P.B. 4016 Basel, Switzerland
Phone +41 61 695 93 95  This email address is being protected from spambots. You need JavaScript enabled to view it.
Registration Office: Organizers Schweiz GmbH, CLINAM SUMMIT 9/2016
Obere Egg 2, CH 4312 Magden, Switzerland
Phone +41 61 836 98 78  This email address is being protected from spambots. You need JavaScript enabled to view it.


Congress Center Basel, Messeplatz 21, 2058 Basel 2nd Floor, Switzerland, Phone +41 58 206 28

The Collaborators of the European and Global CLINAM-Summit 2016

Federal Department of Economic Affairs, Education and Research of the Swiss Confederation, Bern (CH)  BioNanoNet Forschungs-GmbH, Graz (A) Cantons of Basel-Stadt (CH) Chinese Academy of Sciences, Beijing (RC)De Gruyter – European Journal of Nanomedicine, Berlin (D) DIA Europe, Middle East & Africa, Basel (CH) EMPA, Swiss Federal Laboratories for Materials Science, Dübendorf (CH) European Academy of Sciences and Arts, Salzburg (A) European Commission, Brussels (B) • European Forum for Good Clinical Practice EFGCP), Brussels (B) • European Materials Research Society, Strasbourg (F) • European Medicines Agency (EMA), London (UK) • European Society for Nanomedicine, Basel (CH) • European Technology Platform of Nanomedicine (ETPN) • Euro Nanotox Letters (A) • Food and Drug Administration, (FDA) Silver Spring (USA) Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken (D) • Innovative Medicines Initiative, (IMI) Brussels • International Association for Pharmaceutical Technology (APV), Mainz (D) Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Beijing (RC)Lundbeckfonden Center of Excellence NanoCAN, Odense (DK) • National Institute of Health Sciences of Japan, Tokyo (J) National Center for Nanoscience and Technology of China, Beijing (RC) Non Biological Complex Drugs Working Group, (NBCD) Leiden(NL) • Nanotech Characterization Laboratory, National CancerInstitute, Frederick (USA) • University of Basel, Basel (CH)

The Sponsors of the European and Global CLINAM-Summit 2016

• Federal Department of Economic Affairs, Education and Research of the Swiss Confederation, Bern (CH) • Actelion Pharmaceuticals Ltd. Allschwil (CH) • Freiwillige Akademische Gesellschaft Basel, • The Canton of Basel-Stadt(CH) • The Canton of Basel-Land (CH) • Clariant International AG, Pratteln (CH) • Isaac Dreyfus Bernheim Foundation, Basel (CH) • European Materials Forum, Brussels (B) • European Materials Research Society (E-MRS), Strasbourg (F) • GAG AG, Basel (CH) • Löffler & Associates GmbH - Concept Engineering, Basel (CH) • Lonza Ltd., Basel (CH) • Novartis (CH) • Roche (CH) • Swiss NanoScience Institute, Basel • Swiss National Science Foundation, Bern (CH) • Tarveda Therapeutics, Watertown, MA (USA) • TecoMedical Group, Sissach (CH)

Scientific Committee

Prof. Dr. med. Patrick Hunziker, University Hospital Basel (chairman) • Prof. Dr. med. Christoph Alexiou, University Hospital Erlangen (D) • Prof. Dr. Lajos Balogh, AA Nanomedicine and Nanotechnology Consultants, North Andover, Massachusetts and Member of the Executive Board, American Society for Nanomedicine, Boston (USA) • Prof. Dr. Gerd Binnig, Nobel Laureate, Munich (D) • Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL) • Prof. Dr. med. Omid Farokhzad, Associate Professor and Director of Laboratory of Nanomedicine and Biomaterials, Harvard Medical School and Brigham and Women's Hospital, Founder of BIND Therapeutics, Boston (USA) • Prof. Dr. med. Dong Soo Lee, PhD. Chairman Department of Nuclear Medicine Seoul National University Seoul (KOR) • Dr. med. h.c. Beat Löffler, MA European Foundation for Clinical Nanomedicine, Basel (CH) • Prof. Dr. Jan Mollenhauer, Lundbeckfonden Center of Excellence NanoCAN, University of Southern Denmark, Odense (DK) • Prof. Dr. med. Marisa Papaluca Amati, European Medicines Agency, London (UK) • Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, (NL) • Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH)

Introduction – The Conference at a Glance

In the previous eight years, the CLINAM Summit grew to the largest in its field with 12 presenting Noble Laureates and more than 500 participants from academia, industry, regulatory authorities and policy from over 40 different countries in Europe and worldwide. With this success and broad support by well beyond 20 renowned collaborating initiatives, the CLINAM-Summit is today one of the most important marketplaces for scientific exchange and discussions of clinical, regulatory, political and ethical aspects in this field of cutting-edge medicine. The CLINAM Summit emerged as exquisite forum for translation from bench to bedside for European and international networking, for industrial collaboration between companies, with academia, and as point-of-contact with customers. The summit is presently the only place to meet the regulatory authorities from all continents to debate the needs of all stakeholders in the field. CLINAM 9/2016 continues with its tradition to cover the manifold interdisciplinary fields of Clinical and Targeted Nanomedicine in major and neglected diseases. As special focus area, CLINAM 09/2016 adds translation and enabling technologies, including, for example, cutting-edge molecular profiling, nano-scale analytics, single cell analysis, stem cell technologies, tissue engineering, in and ex vivo systems as well as in vitro substitute systems for efficacy and toxicity testing. CLINAM 09/2016 covers the interdisciplinary spectrum of Nanomedicine and Targeted Medicine from new materials and enabling technologies over diagnostic and therapeutic translation to clinical applications in infectious, inflammatory and neurodegenerative diseases, as well as diabetes, cancer and regenerative medicine to societal implications, strategical issues, and regulatory affairs. The conference is sub-divided into three different tracks running in parallel and provides ample possibilities for exhibitors as indicated by steadily increasing request. This year the Nobel Laureate Prof. Stefan Hell will open the Summit. Participants are invited to bring samples to try the reality of the Stimulated Emission Depletion (STED) Microscopy in the exhibition.

The Tracks of the Summit

Track 1: Clinical and Targeted Nanomedicine – Basic Research • Disease Mechanisms and Personalized Medicine
Regenerative MedicineNovel Therapeutic and Diagnostic ApproachesActive and Passive TargetingTargeted Delivery (antibodies, affibodies, aptamers, and nano drug delivery devices) • Accurin Technology •Nano-Toxicology Track 2: Clinical and Targeted Nanomedicine: Translation• Unsolved Medical ProblemsPersonalized Medicine and Theranostic ApproachesRegenerative MedicineAdvanced Breaking and Ongoing Clinical TrialsApplied Nanomedical Diagnostics and Therapeutics Track 3: Enabling Technologies• Nanomaterial Analytics and Testing
• Molecular Profiling for Research and Efficacy/Toxicology Testing (Genomics, Proteomics, Glycomics, Lipidomics, Metabolomics) • Functional Testing Assays and Platforms• Single Cell Analyses • Cell Tracking • Stem Cell Biology and Engineering Technologies • Microfluidics • Tissue Engineering – Tissues-on-a-Chip – Bioprinting •In vivo Testing •Novel Imaging Approaches • Medical Devices Track 4: Regulatory, Societal Affairs and Networking • Regulatory Issues in Nanomedicine • Strategy and Policy • The Patients` Perspective • Ethical Issues in Nanomedicine • University Village • Cutting-Edge EU-Project Presentations • Networking for International Consortium Formation 5. The Exhibition • Based on last year’s exhibition it is expected to have about 30 Exhibitors at this Summit.
• Exhibitors can profit of the possibility to meet their target visitors on 1 single spot in Basel at CLINAM 9 / 2016.
• With its concept for the exhibition, the international CLINAM Summit becomes the place for the pulse of the market and early sales in the field of cutting-edge medicine. 6. University Village and Small Speeches Session for Poster submitters and Village members • The University Village is the space for universities and research institutes, giving them opportunity to present novel approaches, new research projects and initial outcomes of research and experimental results as well as first patents. • Researchers and engineers can use the foyer to show the existing tools, instruments and materials in the field of regenerative medicine, diagnostics, targeted drug delivery systems, novel materials for nanoparticles, imaging, biomaterials / biosensors / biomarkers, Nanomedicine-related medical tools and medical instrumentation as well as existing nanobased clinical medications. • Poster presenters and University Village members are eligible for presentationsin a special session of Small Speeches, 3 minutes in length and serving to highlight the research activities in Nanotechnology and Targeted Medicine. They must comprise three slides, • Slide 1: general introduction to the topic • Slide 2: some of the highlights of submitters’ work and institutions’ work • Slide 3: the proof as to how the work fits into the area of Nanomedicine including a glimpse into the future. Application for Small Speeches Sessions is possible any time after acceptance of your poster in writing. Since there are so many applications a selection has to be done.

Ongoing Call for Posters

The call for oral presentations was closed on April 25. Deadline for “Poster Only” Submission is May 15, 2016. Later submitted Posters until 8 days before the Summit can still be accepted but will not be included in the Summit-Proceedings.

Knowledge Fields and Scope for posters are:

CLINAM invites on interdisciplinary level members in the field of Clinic, Engineering, Industry, Venture, all related Science Faculties, young members from universities and academies and highly skilled youngsters, political decision makers that work in the field and members of regulatory authorities to submit abstracts for papers and posters,

They must cover original research aimed at future or current applications of nanoscience and targeted medicine including clinical trial designs, reports of ongoing and processes, eye and ear disease, tuberculosis, HIV, Ebola, tissue repair, orthopedics, …etc. • Technology: Nanosystems, nanoparticles, nanoanalytics and diagnostics, toxicology, nano-imaging, targeted drug delivery using nanoparticles, GMP and quality assurance, propositions for solving a medical problem in a novel way by the use of nanotechnology, novel concepts and ideas if they can be supported by thorough reasoning and could lead to novel research and solutions, materials for use in nanotechnology and targeted medicine, concepts, diagnosis and therapy in the field of personalized medicine: clinical diagnosis and management on the individual patient's clinical signs and symptoms, medical and family history, and data from laboratory and imaging evaluation to diagnose and treat illnesses, genetic testing leading to more personalized treatments. Also relevant novel tools for translational research and diagnostics are of high interest, etc.… • Implications: Implications of Nanomedicine for society, developing countries, environment, risks and benefits, public health finance, health economics, and other subjects, etc. • Strategy, Government and Politics: Strategy building and policy processes in Nanomedicine. Strategic approaches towards establishing a unified funding area for nanotechnologies for medical research. Policy processes to foster leadership in Nanomedicine, regulatory authority topics as well as financial and marketing matters etc. • Industry Industry projects and solutions in Nanomedicine and targeted medicine, tools related to Nanomedicine and targeted medicine. Industry models for the Future large-scale production, Good Manufacturing Practice, etc. • Exhibitors Integrated interventions of exhibitors of scientific or technical relevance and do not have the solely the purpose of promoting the trademark.

Sending Paper Abstract / Poster Abstract, Format, Procedure

• All correspondence regarding Submission of Posters has to be sent to: This email address is being protected from spambots. You need JavaScript enabled to view it.abstract of poster abstract, (Microsoft Word, RTF, or Open document file format, using Times New Roman, font size 11, single spacing NO PDF). The submission must not be longer than three pages, including metadata and figures (one figure is obligatory). All illustrations, must be placed within the text at the appropriate points.) For control purposes you may send in addition for above text a pdf).Index your file as follows: Last name.First name_Submission16.xx (xx = docx, or rtf, doc or word 13 document).CV Add a short narrative CV (1 page maximum) and index as follows: Last name.First name_CV16.xx Portrait Photo Send us a head picture (in gif or jpg 600 dpi and not word copy paste!) Index your file as follows: Last name.First of the abstractName­_Picture16.xx

Decision for Acceptance

Decision for Acceptance or Declination will be given soon after submission (about 2 weeks) You will then receive Decision Form, which – in the case of acceptance - has to be returned within 3 days of receipt. After this, you have to registeraccording to your category within 5 days.

Presentation Times, Size of Posters, Installation of Posters 

Posters will be located in the Foyer visible for all conference attendees. The meeting breaks and lunches will be the preferred time to study the posters. During lunch and breaks, the authors are asked to be present close to their poster.  Posters are to be presented in the size of 1.40 meter high and 1.00 meter wide. There will be the CLINAM-Poster Prize. Poster installation is on June 27 as from 06.30 until 8.00 h latest and the posters can be removed on June 29, after 4.45 h and latest until 18.00 h pm. The Poster Prize will be handed out during Lunchtime on Wednesday, June 29, 2016.

The Exhibitors at CLINAM 9 / 2016

The Sponsors


The Foundation

The European Foundation for Clinical Nanomedicine is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of nanoscience. Aiming at prevention, diagnosis, and therapy through nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of nanoscience on medicine and the observed rapid advance of medical applications of nanoscience have been the main reasons for the creation of the Foundation.

Nanotechnology for Medicine

Nanotechnology is generally considered as the key technology of the 21st century. It is an interdisciplinary scientific field focusing on methods, materials, and tools on the nanometer scale, i.e. one millionth of a millimeter. The application of this science to medicine seeks to benefit patients by providing prevention, early diagnosis, and effective treatment for prevalent, for disabling, and for currently incurable medical conditions.